West Pharmaceutical Services Beats Q2 Estimates, Raises Guidance on GLP-1 Demand

West Pharmaceutical Services (WST) reported second-quarter CY2026 revenue of $872.3 million, beating analyst estimates of $842.7 million, with 13.8% year-on-year growth, and adjusted earnings per share of $2.37 versus estimates of $2.08. Management raised full-year revenue guidance to $3.36 billion at the midpoint and full-year adjusted EPS guidance to $8.95 at the midpoint. The company’s shares have risen 32.9% year to date, outpacing the industry’s 30.3% decline and the S&P 500 Index’s 28.2% increase.

In the first quarter of 2026, West Pharma reported revenues of $845 million, up 21% year over year, while adjusted EPS surged 47%. High-Value Product (HVP) components, which account for nearly half of the company's revenues, delivered 23% organic growth in the first quarter. GLP-1 products accounted for 10% of total company sales, with demand supported by broader insurance coverage, reduced drug pricing and new indications. Biologics-related business grew 26% organically in the first quarter, benefiting from strong commercial wins and growing adoption of its premium NovaPure packaging solutions. European Annex 1 sterile manufacturing regulations drove a 66% year-over-year increase in Annex 1-related projects, with management expecting these initiatives to contribute approximately 200 basis points to 2026 revenues. Adjusted operating margin improved 350 basis points to 21.4% in the first quarter.

In the second quarter, operating margin was 20.5%, in line with the same quarter last year. The CEO attributed the outperformance to robust growth in Proprietary Products, particularly high-value product components for biologics and biosimilars, and highlighted the company's strong recovery following a cyber incident and expansion of advanced containment solutions. On the earnings call, management described non-GLP-1 HVP component growth as a "multiyear opportunity," cited productivity improvements at Eschweiler, nearing target utilization at Grand Rapids, and ongoing ramp-up at Dublin, and said China and India are primary contributors to Asia Pacific growth, particularly in GLP-1 biosimilars.

Wolfe Research upgraded WST to Outperform from Peer Perform on June 2, assigning a $375 price target, which represents 40 times projected 2027 EPS. The firm noted the stock has historically traded around 40 times earnings over the past 15 years and at a premium of more than 100% to the S&P 500. Morgan Stanley increased its price target to $325 from $315 on May 29, reiterating an Equal Weight rating, saying it "sensed strong conviction in both near- and longer-term execution."

West Pharma completed the divestiture of SmartDose 3.5mL manufacturing rights to AbbVie for $112.5 million, and will focus on more scalable delivery platforms like SmartDose 10mL. The company expanded its Dublin manufacturing facility to support high-volume injectable therapies, particularly next-generation GLP-1 treatments, and commercially launched Synchrony S1 prefillable syringe systems. In February 2026, the company reported fourth-quarter 2025 sales of $805.0 million with net income of $132.1 million, and issued 2026 guidance of $3.215–3.275 billion in net sales with mid-single-digit organic growth.

Competition remains significant from Baxter International and Becton Dickinson (BD). Baxter reported only 3% reported sales growth while facing infusion pump disruptions, manufacturing cost inflation and tariff pressure. BD reported 2.6% revenue growth and double-digit expansion across biologic drug delivery and advanced monitoring platforms. Rising oil and commodity costs could pressure margins.